An official website of the United States government
Home
Name
Zongertinib
Alternate Names
Hernexeos
Abbreviations
None
Category
Chemotherapy
Subcategory
NSC Number
NSC-85453
Primary Site
lung
Histology
non-squamous NSCLC
Remarks
On 2/26/2026 FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test as first line of treatment
On August 8, 2025, the FDA granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test (Oncomine Dx Target Test), and who have received prior systemic therapy.
On August 8, 2025, the FDA granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test (Oncomine Dx Target Test), and who have received prior systemic therapy.
Coding
This drug should be coded
